2026 · 3rd Quarter (July 1 - Sep 30)

AMGEN, INC.

Filed by AVENUE SOLUTIONS.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: AVENUE SOLUTIONS
Client: AMGEN, INC.
Filing UUID: b8c1a0cb-0b21-4178-8dc9-f6147480f332
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act

Literal federal measure citations: H.R. 4299, H.R. 5526, S. 1954, H.R. 10628, S. 5571

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.